top of page

Argenx's CEO on using FcRn to target IgG mediated autoimmune diseases

Tim Van Hauwermeiren describes the science behind argenx's success, the potential market potential, pipeline programs, and his thoughts on European biotech.




Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page